Neurocrine Biosciences IncNASDAQ:NBIX
- LAST PRICE133.8750
- TODAY'S CHANGE (%)3.0150 (2.3040%)
- Bid / Lots133.7200/ 2
- Ask / Lots134.0300/ 4
- Open / Previous Close130.2100 / 130.8600
- Day Range
- 52 Week Range
- Volume260,695
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NBIX |
|---|---|---|
| 09:32 ET | 23286 | 130.645 |
| 09:34 ET | 600 | 129.9 |
| 09:36 ET | 2690 | 130.028 |
| 09:38 ET | 1438 | 129.42 |
| 09:39 ET | 1518 | 129.65 |
| 09:41 ET | 1444 | 129.75 |
| 09:43 ET | 2212 | 130.67 |
| 09:45 ET | 996 | 130.78 |
| 09:48 ET | 1708 | 131.205 |
| 09:50 ET | 1220 | 131.455 |
| 09:52 ET | 1600 | 131.81 |
| 09:54 ET | 3673 | 132 |
| 09:56 ET | 1938 | 131.925 |
| 09:57 ET | 3344 | 131.63 |
| 09:59 ET | 900 | 131.74 |
| 10:01 ET | 2150 | 132.045 |
| 10:03 ET | 11485 | 132.16 |
| 10:06 ET | 800 | 131.95 |
| 10:08 ET | 4031 | 131.94 |
| 10:10 ET | 7526 | 132.15 |
| 10:12 ET | 1927 | 132.16 |
| 10:14 ET | 1800 | 132.26 |
| 10:15 ET | 4674 | 132.42 |
| 10:17 ET | 2200 | 132.575 |
| 10:19 ET | 1231 | 132.555 |
| 10:21 ET | 1895 | 132.455 |
| 10:24 ET | 1800 | 132.775 |
| 10:26 ET | 1284 | 132.84 |
| 10:28 ET | 3220 | 133.23 |
| 10:30 ET | 700 | 133.195 |
| 10:32 ET | 2523 | 133.33 |
| 10:33 ET | 923 | 133.305 |
| 10:35 ET | 4080 | 133.445 |
| 10:37 ET | 1394 | 133.57 |
| 10:39 ET | 2906 | 133.48 |
| 10:42 ET | 1100 | 133.105 |
| 10:44 ET | 2939 | 132.905 |
| 10:46 ET | 300 | 132.89 |
| 10:48 ET | 317 | 132.74 |
| 10:50 ET | 2079 | 133.115 |
| 10:51 ET | 500 | 133.1 |
| 10:53 ET | 2418 | 133.2 |
| 10:55 ET | 7444 | 133.34 |
| 10:57 ET | 837 | 133.06 |
| 11:00 ET | 4079 | 133.56 |
| 11:02 ET | 1700 | 133.66 |
| 11:04 ET | 4694 | 134.06 |
| 11:06 ET | 2323 | 133.865 |
| 11:08 ET | 400 | 133.74 |
| 11:09 ET | 1005 | 133.875 |
Jun 12, 2024
DJ Neurocrine Is Maintained at Overweight by Morgan Stanley, from 1:14PM ET on Wednesday Jun 12, 2024 by Dow Jones
1:14PM ET on Wednesday Jun 12, 2024 by Dow Jones
Jun 3, 2024
Neurocrine Biosciences Presented CAHtalyst(TM) Phase 3 Pediatric and Adult Studies, CAHtalog(TM) Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024, from 8:01AM ET on Monday Jun 03, 2024 by Dow Jones
8:01AM ET on Monday Jun 03, 2024 by Dow JonesNeurocrine Biosciences Announces Publication of Primary CAHtalyst(TM) Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine, from 7:35AM ET on Monday Jun 03, 2024 by Dow Jones
7:35AM ET on Monday Jun 03, 2024 by Dow JonesNeurocrine Biosciences Announces Publication of Primary CAHtalyst(TM) Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine, from 7:30AM ET on Monday Jun 03, 2024 by Dow Jones
7:30AM ET on Monday Jun 03, 2024 by Dow Jones
May 29, 2024
Neurocrine Biosciences to Participate at Investor Conferences in June, from 4:01PM ET on Wednesday May 29, 2024 by Dow Jones
4:01PM ET on Wednesday May 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Neurocrine Biosciences Inc | 13.2B | 36.8x | +62.04% |
Medpace Holdings Inc | 12.5B | 40.7x | +35.10% |
United Therapeutics Corp | 13.6B | 14.6x | +8.22% |
Qiagen NV | 9.7B | 27.7x | +12.66% |
Sarepta Therapeutics Inc | 11.1B | 1,494.6x | --- |
Biomarin Pharmaceutical Inc | 16.0B | 80.2x | --- |
Company Information
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
Contact Information
- Headquarters
- 6027 EDGEWOOD BEND COURTSAN DIEGO, CA, United States 92130
- Phone
- 858-617-7600
- Fax
- 858-617-7602
Executives
- Non-Executive Independent Chairman of the Board
- William Rastetter
- Director
- Kevin Gorman
- Chief Financial Officer
- Matthew Abernethy
- Chief Human Resource Officer
- Julie Cooke
- Chief Scientific Officer
- Jude Onyia
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $13.2B |
|---|---|
Revenue (TTM) | $2.0B |
Shares Outstanding | 100.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.36 |
EPS | $3.64 |
Book Value | $22.61 |
P/E Ratio | 36.8x |
Price/Sales (TTM) | 6.6 |
Price/Cash Flow (TTM) | 33.6x |
Operating Margin | 23.43% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
